Genetic/Molecular Test · 81220
Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants
What Medicare pays for 81220, what providers bill, and how the price varies across 6 states, drawn from CMS 2023 claims data.
- $537.05
- Medicare pays
- $948.28
- Providers bill
- 1.8×
- Markup
- #6,459 of 9,297
- Volume rank
The verdict
Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants pairs modest national service volume with one of the smaller markups in the catalog.
- 31st pct.
- national service volume
- 3rd pct.
- billed-to-Medicare markup
- 1.8×
- billed vs. Medicare
- $537.05
- Medicare pays, national avg
Volume percentile ranks this code's national service volume against every tracked procedure; markup percentile ranks its billed-to-Medicare ratio the same way. The same two figures drive both the verdict sentence and the chips above.
According to the Centers for Medicare & Medicaid Services (CMS), the 2023 Medicare Physician & Other Practitioners dataset records payments for 9,297 procedure codes billed across 5,426 hospitals in 56 states and territories; see our methodology for how each figure is sourced and computed.
Jurisdiction coverage for this code
56states and territories in the CMS extract
Price Range Across States
What You Might Pay
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
How we estimate these prices
These estimates are based on the RAND Hospital Price Transparency Study (4th Edition, 2024). We map each PlainProcedure category onto a RAND CPT-section bucket (Surgery, Radiology, Pathology and Laboratory, Medicine, Anesthesia, Evaluation and Management) or fall back to the national average when no bucket matches. For Genetic/Molecular Test, the applied ratio is 1.85x Medicare (RAND 2024 Pathology and Laboratory bucket (1.85x) + CMS Medicare baseline). Cash/self-pay estimates blend typical cash discounts (55% of billed charges) with Medicare-based estimates (150% of allowed amounts). These are statistical estimates, not quotes. Contact your insurer or provider for actual costs.
Where this markup sits nationally
Markup (billed ÷ Medicare) across 8,901 procedures with a meaningful Medicare rate
2 more affordable than 3% of 8,901 procedures
Each bar is a 1-wide band; taller bars hold more procedures. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Physician & Other Practitioners · 2023
What the billed charge breaks down into
$948.28
Prices by State
| State | Medicare Payment | Billed Charge |
|---|---|---|
| Illinois | $545.47 | $569.33 |
| Massachusetts | $545.47 | $826.10 |
| New Jersey | $545.47 | $628.19 |
| North Carolina | $541.09 | $792.04 |
| New York | $537.38 | $1,504.34 |
| Minnesota | $475.95 | $578.53 |
What the Data Says About Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants
Across 6 states with reporting providers, CPT code 81220 (Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants) shows a national average Medicare payment of $537.05 against an average billed charge of $948.28. That gap, a 1.8x markup, or 77% above the Medicare allowed amount, is among the tightest billed-to-paid spreads we track, this code's chargemaster rate tracks unusually close to the Medicare benchmark.
Genetic/Molecular Test procedures like this one saw 274 services billed to Medicare in 2023 by 34 distinct providers, serving 274 unique beneficiaries. State-level variation is significant: Minnesota reports the lowest average payment at $475.95, while Illinois reports the highest at $545.47. The 15% spread here is a moderate, fairly ordinary GPCI effect, local cost-of-practice adjustments nudging the allowed amount up or down without reshaping it. Applying the RAND 2024 commercial-to-Medicare ratio for this category (1.85x Medicare; RAND 2024 Pathology and Laboratory bucket (1.85x) + CMS Medicare baseline), the estimated commercial insurance price lands near $993.54, with self-pay cash discounts commonly bringing the figure closer to $663.57. Within Genetic/Molecular Test, Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants ranks #100 of 298 tracked procedures by national average Medicare payment.
Where this sits in the registry
Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants (81220) is a CMS 2023 Part B code. These pages keep the volume map and the markup map separate.
- National volume versus markup on the statistics page, the same two maps as this capsule. Statistics
- Other Genetic/Molecular Test codes, ranked by Medicare payment inside the category. Category
- How volume rank and markup rank are computed. Methodology
- The full procedures listing in volume order. Procedures
Figures here are CMS averages, not a quote for any patient, plan, or visit.
Frequently Asked Questions
Where does Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants rank among Medicare procedures?
According to CMS Medicare Part B claims, Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants (CPT 81220) ranks #6,459 of 9,297 procedures by national service volume, the same sort as the procedures listing, and #100 of 298 within Genetic/Molecular Test by national average Medicare payment. See /methodology#corpus-placement.
How much does Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants cost?
Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants (CPT 81220) is priced fairly consistently nationwide: Medicare pays $537.05 on average, and the $475.95-$545.47 state range stays relatively tight. Providers typically bill $948.28.
Why do providers charge more than Medicare pays?
Providers set their own chargemaster rates (billed charges), which are typically much higher than what any insurer pays. Medicare pays a fixed rate based on the procedure code and geographic location. The billed charge is relevant mainly for uninsured patients, who may face prices closer to the submitted charge.
How much does Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants cost with insurance?
With commercial insurance, gene analysis (cystic fibrosis transmembrane conductance regular) common variants costs an estimated $993.54 on average (range: $695.48-$1,390.96), a moderate premium over Medicare's $537.05. Without insurance, the estimated cash price is $663.57.
Which state has the lowest cost for Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants?
Minnesota and Illinois bookend the range for Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants, at $475.95 and $545.47 respectively - a relatively tight $69.52 spread nationwide.
How many providers perform Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants?
Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants is comparatively uncommon: only 34 providers nationally billed Medicare for it in 2023, serving 274 beneficiaries via 274 total services.
What is the billed-to-Medicare markup for Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants?
Providers bill 1.8x what Medicare pays for Gene Analysis (cystic Fibrosis Transmembrane Conductance Regular) Common Variants - one of the smaller markups in the catalog at 77% above the Medicare rate.
Nationwide similar CPT codes
Data-derived peers across the CMS Physician & Other Practitioners extract: nearest national service volume and nearest average Medicare payment. Not clinical substitutes: claim-mass and payment neighborhoods only.
Closest national service volume
Nearest codes with ≥100 services (274 here).
Closest average Medicare payment
Nearest codes with payment ≥ $5 ($537.05 here).
Related Guides
Tips to reduce out-of-pocket costs
Your right to upfront pricing
How Medicare payments work
Decode charges and codes
Why bills exceed actual costs
Geographic pricing factors
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainProcedure is rendered directly from CMS Medicare Physician & Other Practitioners data, no number is typed in by an editor. This page draws directly on CMS Medicare Physician & Other Practitioners data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.